Explore the Weight Loss Effect of Amway "BODY TRIMMER"
NCT07924956, Not applicable, Recruiting, Amway (China) R&D Center
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Explore the Weight Loss Effect of Amway "BODY TRIMMER" | ClinicalTrials.gov |
| NCT number | NCT07924956 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 110 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Amway (China) R&D Center | ClinicalTrials.gov |
| Conditions | Abdominal Obesity | ClinicalTrials.gov |
| Interventions | Body trimmer intervention dose 1, Body trimmer intervention dose 2 | ClinicalTrials.gov |
| First posted | 2026-11-09 | ClinicalTrials.gov |
| Last updated | 2026-11-09 | ClinicalTrials.gov |
Registered outcomes 31
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Weight | baseline day 0,week4,week8,week12 | Changes from weight in the high-dose, low-dose and blank control groups. | ClinicalTrials.gov |
| Secondary | Blood Pressure | baseline day 0,week4,week8,week12 | Between-group changes across the high-dose group, low-dose group, and blank control group at baseline, 4-week, 8-week, and 12-week follow-up; within-group changes in the high-dose group and low-dose group from baseline to 12-week follow-up. Both systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be measured. | ClinicalTrials.gov |
| Secondary | BMI (Body Mass Index) | baseline day 0,week4,week8,week12 | Between-group changes across the high-dose group, low-dose group, and blank control group at baseline, 4-week, 8-week, and 12-week follow-up; within-group changes in the high-dose group and low-dose group from baseline to 12-week follow-up. | ClinicalTrials.gov |
| Secondary | Improvement of Fat and Muscle Portions and Body Fat Percentage measured by Inbody S10 or S770 from baseline | baseline day 0,week12 | Body composition consists of specific body components including fat, protein, minerals and body water measured by Inbody S10 or S770.Within-group changes in the high-dose group and low-dose group from baseline to 12-week follow-up; between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up. | ClinicalTrials.gov |
| Secondary | Changes from baseline in abdominal fat (Android fat % and Gynoid fat %) measured by dual-energy X-ray absorptiometry (DXA). | baseline day 0,week12 | Within-group changes in the high-dose group and low-dose group from baseline to 12-week follow-up; between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up. | ClinicalTrials.gov |
| Secondary | Blood Lipids | baseline day 0,week12 | Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up. | ClinicalTrials.gov |
| Secondary | Blood Glucose | baseline day 0,week12 | Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up. | ClinicalTrials.gov |
| Secondary | Serum Insulin | baseline day 0,week12 | Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up. | ClinicalTrials.gov |
| Secondary | C-reactive protein (CRP) | baseline day 0,week12 | Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up. | ClinicalTrials.gov |
| Secondary | 1L-6 | baseline day 0,week12 | Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up. | ClinicalTrials.gov |
| Secondary | Glycated Hemoglobin (HbA1c) | baseline day 0,week12 | Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up. | ClinicalTrials.gov |
| Secondary | Appetite Visual Analogue Scale (VAS) | baseline day 0,week4,week8,week12 | Visual Analogue Scale (VAS) The VAS was used to assess satiety, with scores ranging from 0 to 30 points. * 0-10 points: Good satiety: moderate appetite, weak hunger sensation, low food intake, favorable for weight loss * 11-20 points: Moderate satiety: balanced appetite and hunger, normal food intake, generally controllable * 21-30 points: Poor satiety: strong appetite, intense hunger sensation, large food intake, unfavorable for weight loss | ClinicalTrials.gov |
| Secondary | Dietary Pattern and Fat Intake Assessment (total score: 10-40 points) | baseline day 0,week4,week8,week12 | * 35-40 points: Excellent diet Regular and healthy dietary pattern, low oil and sugar intake, sufficient vegetable consumption, limited high-fat foods * 28-34 points: Good diet Generally healthy diet; fat and snack intake are manageable * 20-27 points: Fair diet Relatively high fat intake; frequent take-out meals and snacks; dietary adjustments are needed * 10-19 points: Poor diet High-oil and high-sugar diet; frequent take-out and fried foods; major barriers to weight loss | ClinicalTrials.gov |
| Secondary | Physical Activity Assessment (total score: 3-12 points) | baseline day 0,week4,week8,week12 | * 10-12 points: Excellent physical activity Regular exercise with adequate duration and high daily activity level * 7-9 points: Good physical activity Established exercise habits; activity levels meet requirements * 5-6 points: Fair physical activity Occasional exercise; predominantly sedentary daily lifestyle * 3-4 points: Poor physical activity Virtually no exercise; prolonged sedentary behavior; insufficient energy expenditure | ClinicalTrials.gov |
| Secondary | Alanine Aminotransferase (ALT) | baseline day 0,week12 | Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up. | ClinicalTrials.gov |
| Secondary | Aspartate Aminotransferase (AST) | baseline day 0,week12 | Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up. | ClinicalTrials.gov |
| Secondary | Alkaline Phosphatase (ALP) | baseline day 0,week12 | Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up. | ClinicalTrials.gov |
| Secondary | Gamma-Glutamyl Transferase (GGT) | baseline day 0,week12 | Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up. | ClinicalTrials.gov |
| Secondary | Total Bilirubin (TBIL) | baseline day 0,week12 | Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up. | ClinicalTrials.gov |
| Secondary | Direct Bilirubin (DBIL) | baseline day 0,week12 | Between-group comparisons among the high-dose group, low-dose group, and blank control group at 12-week follow-up. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)